Definium Therapeutics（DFTX）株式概要
臨床バイオ医薬品企業であるディフィニウム・セラピューティクス社は、脳の健康障害を治療する新規製品候補を開発している。 詳細
DFTX Community Fair Values
Create NarrativeSee what 68 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Definium Therapeutics, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$44.19 |
| 52週高値 | US$49.20 |
| 52週安値 | US$6.95 |
| ベータ | 2.21 |
| 1ヶ月の変化 | 87.64% |
| 3ヶ月変化 | 116.30% |
| 1年変化 | 516.32% |
| 3年間の変化 | 1,081.55% |
| 5年間の変化 | -16.31% |
| IPOからの変化 | 407.41% |
最新ニュース
Recent updates
ナラティブの更新 • Jun 26
DFTX: Phase 3 Depression Data Will Likely Prove Priced In
Definium Therapeutics' updated fair value estimate has moved from $20.00 to about $35.66 as analysts raise price targets into the $57 to $74 range, citing strong Phase III EMERGE data for DT120 in major depressive disorder and increased confidence in the program across additional indications. Analyst Commentary Recent Street research on Definium Therapeutics centers on the Phase III EMERGE data for DT120 in major depressive disorder, with multiple firms updating their models and adjusting price targets to reflect the reported effect size, durability of response, and safety profile.Seeking Alpha • Jun 23
Definium: Phase 3 MDD Data Wins Over Wall Street, But Caution Still Advised
Summary Definium Therapeutics surged ~50% after positive Phase 3 EMERGE data for DT120 in major depressive disorder, demonstrating rapid, robust, and durable efficacy. DTFX's DT120 showed a -8.1 point MADRS score improvement over placebo at week 6, with promising safety and single-dose administration in a controlled setting. Despite $373.4m cash and a $500m raise, DTFX's $4bn pre-commercial valuation appears high given remaining regulatory, commercial, and competitive uncertainties. I maintain a Hold rating, preferring to await upcoming Phase 3 GAD and ASCEND MDD data to clarify DT120’s risk/reward profile before considering a more bullish stance. Read the full article on Seeking Alpha
新しいナラティブ • Apr 02
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelics-based medicines for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 19
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Catalysts About Definium Therapeutics Definium Therapeutics develops late stage psychedelic based therapies targeting psychiatric and neurodevelopmental disorders. What are the underlying business or industry changes driving this perspective?新しいナラティブ • Mar 04
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelic based treatments for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 21
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Summary Initiating coverage on Mind Medicine with a Hold rating due to regulatory uncertainties around rescheduling Schedule I compounds for medical use. Despite strong cash resources and promising Phase 3 trials, regulatory delays could hinder MNMD's patient access and market entry. The global GAD, MDD, and ASD markets present significant growth opportunities, but MM120 faces competition and unique safety and scheduling issues. Positive Phase 3 outcomes could drive regulatory progress, but until FDA and DEA clear rescheduling, broad patient access and reimbursement remain uncertain. Read the full article on Seeking AlphaSeeking Alpha • Jan 29
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Summary Mind Medicine (MindMed) Inc.'s stock has surged over 160% since my October 2022 “Hold” call, driven by positive Phase 2b data for MM120 in treating GAD. Despite financial stability and promising Phase 3 trials, significant hurdles remain, including DEA rescheduling of LSD and FDA approval challenges. The company faces issues with patenting naturally occurring substances and potential reluctance from insurers and physicians to adopt psychedelic therapies. While MindMed shows progress, I remain cautious due to regulatory and commercial obstacles, maintaining my “Hold” rating on MNMD amidst ongoing uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Nov 04
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Summary Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the first half of 2025, with data expected in late 2026. The company has secured funding through 2027, following a public offering, and burns approximately $24.5 million in cash per quarter. Investors should watch for key milestones in 2026 and consider risks related to trial outcomes and regulatory approval for MM-120 and MM-402. Read the full article on Seeking AlphaSeeking Alpha • Aug 15
Psychedelic Stocks: Focus On Their Cash
Summary Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks. Major players in the psychedelic medicine space are well-funded, moving into Phase 3 trials, with potential for significant milestones in the near future. Read the full article on Seeking AlphaSeeking Alpha • Jun 05
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Summary Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024. The primary endpoint of the phase 2b MMED008 study met with statistical significance of HAM-A score over a 4-week period; Patients were given MM-120 to treat GAD. The global Generalized Anxiety Disorder treatment market is expected to reach $4.26 billion by 2033. MindMed has a backup candidate in its pipeline, MM-402, which still uses MDMA targeting for disorders, but with an improved safety profile; this would be MDMA types R[-]-MDMA, S[+]-MDMA and R/S-MDMA. Read the full article on Seeking AlphaSeeking Alpha • Apr 04
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Summary Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033. MM-402 is being advanced in a phase 1 study for the treatment of patients with ASD with results expected 1st half of 2024; The global autism spectrum disorder market could grow to $3.42 billion by 2030. Read the full article on Seeking AlphaSeeking Alpha • Feb 02
Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Summary Primary endpoint met of HAM-A scores at week 4 met in phase 2b MMED008 study, when Generalized Anxiety Disorder patients were given MM-120. 12-week HAM-A results from phase 2b MMED008 study in GAD to be released end of Q1 of 2024 with full data set at upcoming medical meeting in 2024. End of phase 2 meeting with FDA to discuss advancement of MM-120 for GAD expected in the 1st half of 2024; Phase 3 trial initiation expected 2nd half of 2024. The generalized anxiety disorder market size is estimated to reach $8.1 billion by 2027. Read the full article on Seeking Alpha株主還元
| DFTX | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | -1.7% | 1.4% | 1.6% |
| 1Y | 516.3% | 48.6% | 18.6% |
業界別リターン: DFTX過去 1 年間で48.6 % の収益を上げたUS Pharmaceuticals業界を上回りました。
リターン対市場: DFTX過去 1 年間で18.6 % の収益を上げたUS市場を上回りました。
価格変動
| DFTX volatility | |
|---|---|
| DFTX Average Weekly Movement | 16.3% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: DFTXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: DFTXの weekly volatility ( 16% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| n/a | 106 | Rob Barrow | definiumtx.com |
デフィニウム・セラピューティクス社は臨床バイオ医薬品企業で、脳の健康障害を治療する新規製品候補を開発している。同社の主要製品候補であるDT120は全般性不安障害、大うつ病性障害、その他の脳の健康障害の治療薬として第3相臨床試験中であり、DT402は3,4-メチレンジオキシメタンフェタミンのR-エナンチオマーで自閉症スペクトラム障害の治療薬として第2a相臨床試験中である。同社は以前はマインド・メディシン（MindMed）社として知られていたが、2026年1月にデフィニウム・セラピューティクス社に社名を変更した。本社はニューヨーク州ニューヨーク。
Definium Therapeutics, Inc. 基礎のまとめ
| DFTX 基礎統計学 | |
|---|---|
| 時価総額 | US$5.87b |
| 収益（TTM） | -US$237.54m |
| 売上高(TTM) | n/a |
0.0x
P/Sレシオ-24.7x
PER（株価収益率DFTX は割高か？
公正価値と評価分析を参照収益と収入
| DFTX 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$0 |
| 売上総利益 | US$0 |
| その他の費用 | US$237.54m |
| 収益 | -US$237.54m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.79 |
| グロス・マージン | 0.00% |
| 純利益率 | 0.00% |
| 有利子負債／自己資本比率 | 14.6% |
DFTX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/05 17:54 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Definium Therapeutics, Inc. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22
| アナリスト | 機関 |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |